A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer
NCT05103826 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3
Last updated 2023-08-15
Summary
The study is being conducted to assess the safety 、tolerability 、 pharmacokinetics and efficacy of SHR6390 combined with famitinib in the treatment of ER + / HER2- advanced breast cancer.
Conditions
- ER+ / HER2- Advanced Breast Cancer
Interventions
- DRUG
-
SHR6390、Famitinib
SHR6390, oral;Famitinib, oral.
Sponsors & Collaborators
-
Jiangsu HengRui Medicine Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-10-25
- Primary Completion
- 2023-06-15
- Completion
- 2023-06-15
Countries
- China
Study Locations
More Related Trials
-
SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer
NCT03596658 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer
NCT03993964 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
NCT05635487 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients
NCT06788197 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
NCT04095390 ·Status: UNKNOWN ·Phase: PHASE2
-
SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.
NCT04836520 ·Status: COMPLETED ·Phase: PHASE2
-
SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response
NCT07129187 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
NCT05792410 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers
NCT05349409 ·Status: UNKNOWN ·Phase: PHASE2
-
Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer
NCT07333937 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer
NCT05085626 ·Status: UNKNOWN ·Phase: PHASE2
-
Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer
NCT03772353 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
NCT05814354 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer
NCT04993430 ·Status: UNKNOWN ·Phase: PHASE1
-
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
NCT03945604 ·Status: COMPLETED ·Phase: PHASE1
-
Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative
NCT04842617 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer
NCT07132242 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
NCT07041437 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
NCT06057610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer
NCT01937689 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
NCT03966898 ·Status: UNKNOWN ·Phase: PHASE3
-
A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
NCT04513223 ·Status: COMPLETED ·Phase: PHASE1
-
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
NCT05656131 ·Status: SUSPENDED ·Phase: PHASE2
-
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
NCT06015048 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
NCT04446260 ·Status: COMPLETED ·Phase: PHASE1